Servier acquires Edgewise's muscular dystrophy assets for $1.55 billion
read at Endpoints ↗DealPositive
Servier announced it will purchase the muscular dystrophy business from Edgewise Therapeutics.
The deal involves an upfront payment of $1.55 billion, giving the French company rights to Edgewise's experimental neuromuscular medicine.
The asset is expected to generate pivotal data by the end of the year, potentially advancing Servier's therapeutic pipeline.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets”
read at Endpoints ↗81 words · retrieved Jun 1
comments(0)
5-min edit window · permanent after that